Impact Biomedical (IBO) Stock Price

Impact Biomedical Price

NYSE·CLOSED
4.39
​
Market closed

Revenue at Impact Biomedical has contracted by 10.6% per year over the past 4 years to 32,000.00 USD. For Impact Biomedical, the net margin of -36,993.8% is down versus -14,102.0% a few years ago.

Impact Biomedical stock price

Access this data via the Eulerpool API

Impact Biomedical business model & stock analysis

Impact Biomedical Inc is a US-based company operating in industry. The company is headquartered in Houston, Texas and currently employs 1 full-time employees. The company went IPO on 2024-09-16. Impact Biomedical Inc. is a human healthcare company and is a wholly owned subsidiary of DSS, Inc. The Company, through the utilization of its intellectual property rights, or through investment in, or through acquisition of companies in the bio health and biomedical fields, focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The firm is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The Company, through its subsidiary, Global BioLife, Inc., focuses on research in four main areas: the Linebacker project, which develops a universal therapeutic drug platform; a new sugar substitute called Laetose; a multi-use fragrance called 3F (Functional Fragrance Formulation), which is a mosquito fragrance product; and Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.

Frequently asked questions about Impact Biomedical

Converted at the current exchange rate, the Impact Biomedical share trades at 3.92 EUR (4.39 USD).

The revenue cannot currently be calculated for Impact Biomedical.

The profit cannot currently be calculated for Impact Biomedical.

The P/E ratio cannot be calculated for Impact Biomedical at the moment.

The P/S cannot be calculated for Impact Biomedical currently.

The Eulerpool Quality Score for Impact Biomedical is 1/10.

The ISIN of Impact Biomedical is US45259L2051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Impact Biomedical is IBO. The ticker symbol is used to trade Impact Biomedical shares on the stock exchange.

Fair ValueTerminal
4.30 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue per Employee
32,000.00 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Sep 16, 2024
ISIN
US45259L2051
Cusip
45259L205
Market capitalization
473.33 M USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
37.54
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-89.48 %
Last updated Oct 11, 2026, 1:43 AM

Impact Biomedical Peer Group